Heron Therapeutics Announces Submission of HTX-019 NDA for t

Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

, David Szekeres , Cochrane Meta , Ashraf Habib , Exchange Commission , Company Codes , Drug Administration , Heron Therapeutics Inc , Nasdaq , Heron Therapeutics , New Drug Application , Cochrane Meta Analysis , Barry Quart , Chief Executive Officer , Duke University , Private Securities Litigation Reform Act , Media Contact , Vice President , Chief Operating , Resume , Careers , Eron Therapeutics Announces Submission Of Htx 019 Nda For The Prevention Postoperative Nausea And Vomiting To Fda , Iospace , Advice ,